An observational study in Subarachnoid Hemorrhage, Intracerebral Hemorrhage and Traumatic Brain Injury, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Subarachnoid Hemorrhage with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Subarachnoid Hemorrhage · Austria.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, this one is one of 5 that started in 2020, is one of 4 observational ones, and was the 11th registered.
513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.
Browse Subarachnoid Hemorrhage studies →3 of the 14 studies in Subarachnoid Hemorrhage with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–95
Medical University Innsbruck · Sites in Austria
Ages 18–90
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 120 across 227 observational studies indexed under Subarachnoid Hemorrhage.
Median enrollment 247 across the 10 interventional studies, 80 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 2 studies filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Theoretical Framework \& Background
Cortical spreading depressions (CSD) and seizures, are crucial in the development of delayed cerebral ischemia and poor functional outcome in patients suffering from acute brain injuries such as subarachnoid hemorrhage. Multimodal neuromonitoring (MMNM) provides the unique possibility in the sedated and mechanically ventilated patients to record these electrophysiological phenomena and relate them to measures of cerebral ischemia and malperfusion. MMNM combines invasive (e.g. electrocorticography, cerebral microdialysis, brain tissue oxygenation) and noninvasive (e.g. neuroimaging, continuous EEG) techniques. Additionally, cerebral microdialysis can measure the unbound extracellular drug concentrations of sedatives, which potentially inhibit CSD and seizures in various degrees, beyond the blood-brain barrier without further interventions.
Hypotheses
Methods
Systematic analysis of MMNM measurements following standardized criteria and correlation of electrophysiological phenomena with cerebral metabolic changes in all included patients. In a second step neuroimaging, cerebral extracellular sedative drug concentrations and neurological functional outcome, will be correlated with both electrophysiologic and metabolic changes. Due to numerous high-resolution parameters, machine learning algorithms will be used to correlate comprehensive data on group and individual levels following a holistic approach.
Level of originality
Extensive, cutting edge diagnostic methods are used to get a better insight into the pathophysiology of electrophysiological and metabolic changes during the development of secondary brain damage. Due to the immense amount of high-resolution data, a computer-assisted evaluation will be applied to identify relationships in the development of secondary brain injury. For the first time systematic testing of several drug concentrations beyond the blood-brain barrier will be performed. With these combined methods, we will be able to develop new cerebroprotective treatment concepts on an individual basis.
Individuals between 18-80 years with poor grade aneurysmal SAH (World Federation Neurosurgical Societies >3), severe ICH (ICH Score >3) or severe TBI (Glasgow Coma Scale \<9).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Thereafter, the patient has the possibility to withdraw permission of study-participation.
Count of SD during electrocorticography
Count of cortical spreading depolarization (SD) during continuous electrocorticography
Time frame: up to 21 days
Daily pattern duration of CSD during electrocorticography
Duration of cortical spreading depression (CSD) per hour during continuous electrocorticography
Time frame: up to 21 days
Daily pattern duration of NCSE during electrocorticography
Duration of nonconvulsive status epilepticus (NCSE) per hour during continuous electrocorticography
Time frame: up to 21 days
Daily pattern duration of RPPIIC during electrocorticography
Duration of rhythmic or periodic EEG patterns on the ictal-interictal continuum (RPPIIC) per hour during continuous electrocorticography
Time frame: up to 21 days
Daily duration of metabolic crisis
Duration of metabolic crisis (defined as Lactate Pyruvate ratio \[LPR\] \> 40 and lactate higher than 4 mmol/l) during continuous electrocorticography
Time frame: up to 21 days
Daily duration of mitochondrial dysfunction
Duration of mitochondrial dysfunction (defined as LPR \> 40, Pyruvate \> 70 μmol/l and partial brain tissue oxygenation \[PbtO2\] \> 20 mmHg) during continuous electrocorticography
Time frame: up to 21 days
Daily duration of ischemia
Duration of ischemia (defined as PbtO2 \< 15 mmHg and cerebral perfusion pressure \[CPP\] \< 60 mmHg) during continuous electrocorticography
Time frame: up to 21 days
Daily duration of elevated intracranial pressure (ICP)
Duration of elevated intracranial pressure (defined as ICP \> 22 mmHg) during continuous electrocorticography
Time frame: up to 21 days
Neuropharmacology Cmax)
Cmax of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
Time frame: up to 21 days
Neuropharmacology (AUC)
AUC of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
Time frame: up to 21 days
Neuropharmacology (t1/2)
t1/2 of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
Time frame: up to 21 days
Neuroimaging
Absence or presence of hypoperfusion or ischemic infarctions in neuroimaging
Time frame: up to 28 days
Functional patient outcome
modified Rankin Scale
Time frame: up to 6 months
Started Dec 2020 (actual). Primary completion is estimated for Dec 2025, 60 months after the start.
Of 117 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 60 months is above that.
Counting every sponsor, half of 120 studies reached it within 40 months; a quarter within 19 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →